Other research looked at the role of the FPR1 gene using a microfluidic device where immune cell migration towards and interaction with chemotherapy treated cancer cells could be recorded.40 This model was subsequently modified to study PBMC recruitment towards ECM-embedded (Matrigel) cancer cells exposed to decitabine (DAC) and/or IFN.42 Greater infiltration of PBMC was reported toward tumour cells treated with both DAC and IFN in comparison to one agent alone and to untreated cells. This evidence concerns the gene IFNA1 and neoplasm.